Voloridge Investment Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Voloridge Investment Management’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,130	Closed	-$2.64M	–	1601
2022 Q1	$2.64M	Sell	2,130 -101	-5%	-$137K	0.02%	857
2021 Q4	$5.63M	Buy	2,231 +1,883	+541%	+$11.5M	0.03%	680
2021 Q3	$6.37M	Buy	348 +182	+110%	+$2.89M	0.04%	585
2021 Q2	$1.76M	Buy	+166	New	+$1.39M	0.01%	1035
2021 Q1	–	Sell	-164	Closed	-$910K	–	1611
2020 Q4	$910K	Buy	+164	New	+$1.45M	0.01%	995

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Voloridge Investment Management's IRLA Position: Q2 2022 in Review

Voloridge Investment Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 2,130 shares — an estimated $2.64M sold.

Voloridge Investment Management first reported a position in IRLA in Q4 2020 and held it in 5 quarters. The position peaked at $6.37M in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

Voloridge Investment Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Voloridge Investment Management sold 2,130 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $2.64M.
Voloridge Investment Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Voloridge Investment Management's IRulya Therapeutics Inc. Common Stock position peaked at $6.37M in Q3 2021.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Voloridge Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.